November 14, 2012

RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

RET fusion occurs in 1.4% of NSCLCs and 1.7% of lung adenocarcinomas and has identifiable clinicopathologic characteristics, warranting further clinical consideration and targeted therapy investigation.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Wang et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8a88a18b0ca7f91d18bd2 https://doi.org/https://doi.org/10.1200/jco.2012.44.1477

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas2011 · 279 citations
2The impact of translocations and gene fusions on cancer causation2007 · 1,419 citations
3Identification of RET gene fusion by exon array analyses in “pan-negative” lung cancer from never smokers2012 · 79 citations
4<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers2012 · 1,558 citations
5Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis2012 · 175 citations

Preguntar a la IA

Me gusta

Guardar